Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Augmenting randomized clinical trial data with historical control data: Precision medicine applications
Boris Freidlin, Edward L. Korn
JNCI Journal of the National Cancer Institute (2022) Vol. 115, Iss. 1, pp. 14-20
Open Access | Times Cited: 14

Showing 14 citing articles:

Use of Real‐World Data and Real‐World Evidence in Rare Disease Drug Development: A Statistical Perspective
Jie Chen, Susan Gruber, Hana Lee, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 2
Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils
Mei‐Yin C. Polley, Daniel L. Schwartz, Theodore Karrison, et al.
Neuro-Oncology (2024) Vol. 26, Iss. 5, pp. 796-810
Closed Access | Times Cited: 6
On the use of external controls in clinical trials
Michelle M. Nuño, Stephanie L. Pugh, Lingyun Ji, et al.
JNCI Monographs (2025) Vol. 2025, Iss. 68, pp. 30-34
Closed Access
Considerations for master protocols using external controls
Jie Chen, Xiaoyun Li, Chengxing Lu, et al.
Journal of Biopharmaceutical Statistics (2024), pp. 1-23
Open Access | Times Cited: 2
Two-to-One Randomization: Rarely Advisable
Boris Freidlin, Edward L. Korn
JCO Oncology Practice (2024)
Closed Access | Times Cited: 2
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
Alyssa Ylescupidez, Henry T. Bahnson, Colin O’Rourke, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 6
An interpretable framework to identify responsive subgroups from clinical trials regarding treatment effects: Application to treatment of intracerebral hemorrhage
Yaobin Ling, Muhammad Bilal Tariq, Kaichen Tang, et al.
PLOS Digital Health (2024) Vol. 3, Iss. 5, pp. e0000493-e0000493
Open Access | Times Cited: 1
Statistical Considerations in Pediatric Cancer Trials: Report of American Statistical Association Biopharmaceutical Section Open Forum Discussions
Rajeshwari Sridhara, Olga Marchenko, Qi Jiang, et al.
Statistics in Biopharmaceutical Research (2023) Vol. 15, Iss. 4, pp. 845-851
Closed Access | Times Cited: 2
Commentary on Harun et al.: The use of historical controls in randomized clinical trials
Stephen L. George
Clinical Trials (2023) Vol. 20, Iss. 3, pp. 235-236
Closed Access | Times Cited: 1
Clarifying Causal Effects of Interest and Underlying Assumptions in Randomized and Nonrandomized Clinical Trials in Oncology Using Directed Acyclic Graphs and Single-World Intervention Graphs
Shiro Tanaka, Yuriko Muramatsu, Kosuke Inoue
JCO Clinical Cancer Informatics (2024), Iss. 8
Open Access
AUGMENTed Real-World Data Enhances Comparative Efficacy Between Once-Weekly Insulin Icodec with Dosing Guide App Versus Once-Daily Insulin Glargine U300 in Insulin-Naive Type 2 Diabetes
Liana K. Billings, Marisse Asong, Martin Bøg, et al.
Diabetes Therapy (2024)
Open Access
Bias and Randomization in Clinical Trials: 1980s–2020s–2060s
Jay Herson
(2024), pp. 3-17
Closed Access
Weighing evidence: robustness vs quantity
Scott Evans, Toshimitsu Hamasaki
JNCI Journal of the National Cancer Institute (2022) Vol. 115, Iss. 1, pp. 1-3
Open Access | Times Cited: 1
A Standardized Metric to Enhance Clinical Trial Design and Outcome Interpretation in Type 1 Diabetes
Alyssa Ylescupidez, Henry T. Bahnson, Colin O’Rourke, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top